Filip Krag Knop

Filip Krag Knop

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


  1. 2011
  2. Published

    Emerging GLP-1 receptor agonists

    Lund, A., Knop, Filip Krag & Vilsbøll, Tina, 2011, In: Expert Opinion on Emerging Drugs. 16, 4, p. 607-18 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

    Lund, Asger Bach, Vilsbøll, Tina, Bagger, J. I., Holst, Jens Juul & Knop, Filip Krag, 2011, In: American Journal of Physiology: Endocrinology and Metabolism. 300, 6, p. E1038-E1046 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding

    Usinger, Lotte, Hansen, K. B., Kristiansen, V. B., Larsen, S., Holst, Jens Juul & Knop, Filip Krag, 2011, In: Obesity Surgery. 21, 5, p. 625-32 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. 2010
  6. Published

    Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

    Aaboe, K., Knop, Filip Krag, Vilsbøll, T., Deacon, Carolyn F., Holst, Jens Juul, Madsbad, S. & Krarup, T. M., 1 Apr 2010, In: Diabetes, Obesity and Metabolism. 12, 4, p. 323-33 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose- and non-glucose-induced insulin secretion in patients with type 2 diabetes mellitus

    Aaboe, K., Knop, Filip Krag, Vilsbøll, Tina, Deacon, Carolyn F., Holst, Jens Juul, Madsbad, Sten & Krarup, T., 2010, In: Diabetes, Obesity and Metabolism. 12, 4, p. 323-333 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?

    Asmar, M., Bache, M., Knop, Filip Krag, Madsbad, Sten & Holst, Jens Juul, 1 May 2010, In: The Journal of clinical endocrinology and metabolism. 95, 5, p. 2367-75 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

    Christensen, M., Knop, Filip Krag, Vilsbøll, Tina, Aaboe, K., Holst, Jens Juul, Madsbad, Sten & Krarup, T., 9 Aug 2010, In: Regulatory Peptides. 163, 1-3, p. 96-101 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

    Christensen, M. & Knop, Filip Krag, 1 Apr 2010, In: Current Diabetes Reports. 10, 2, p. 124-32 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects

    Hansen, K. B., Vilsbøll, Tina, Bagger, J. I., Holst, Jens Juul & Knop, Filip Krag, 1 Jul 2010, In: The Journal of clinical endocrinology and metabolism. 95, 7, p. 3309-17 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. Published

    Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review

    Hansen, K. B., Vilsbøll, Tina & Knop, Filip Krag, 1 Jan 2010, In: Diabetes, Metabolic Syndrome and Obesity. 3, p. 155-63 9 p.

    Research output: Contribution to journalReviewResearchpeer-review

ID: 40100368